INKT

MiNK Therapeutics (INKT)

About MiNK Therapeutics (INKT)

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Details

Daily high

$9.08

Daily low

$8.48

Price at open

$8.98

52 Week High

$76.00

52 Week Low

$6.34

Market cap

41.4M

Dividend yield

0.00%

Volume

40,871

Avg. volume

850,442

P/E ratio

-2.91

MiNK Therapeutics News